DR-037 Precision Cancer Therapy: Profiting from Tumor Specific Defects and Synthetic Lethality in the DNA Damage Tolerance Network
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-037 Precision Cancer Therapy: Profiting from Tumor Specific Defects and Synthetic Lethality in the DNA Damage Tolerance Network
Tumor-specific defect in the DNA repair offer great potential for DNA damage based chemo/radio therapy. Present data implicate that this …
DR-047 Characterizing mutational profiles of anti-cancer drugs
Anticancer drugs can (in)directly interfere with DNA and thereby potentially generate a characteristic pattern of somatic mutations (mutational signature). Identifying …
DR-046 CPCT-02 Breast NAVIGATOR: Non-invasive monitoring of breast cancer therapy using cell-free tumor DNA in blood
Resistance to therapy is one of the main challenges in treatment of metastatic breast cancer. We know that treatment resistance …
DR-045 DR-009 extension: Lung and melanoma genomic profiles
Immunotherapies stimulate the patients own immune system to kill tumor cells. These relatively new therapies have shown impressive treatment results …
DR-043 Pan-cancer quantification of DNA- and retroviruses
Some cancers are the result of viral infections. A novel type of cancer therapy, called immunotherapy, has been shown to …
DR-041 Quantification and characterization of clustered somatic mutations throughout the pan-cancer metastatic landscape using our custom algorithm KatDetect
Cancer is driven by accumulation of single DNA mutations, but also by catastrophic events involving multiple simultaneous changes. One such …
DR-039 Defining the spectrum of structural variation in 2,500 metastatic cancer genomes
Recent whole genome sequencing efforts have identified a broad spectrum of gains and losses of DNA in cancer genomes. This …
DR-038 Plasticity of estrogen receptor genomics in endometrium tumors
Endometrium cancer is one of the most common gynecological cancer and accounts for approx. 6% of all cancers in women. …
DR-036 The landscape of somatic genetic aberrations in metastases of neuroendocrine tumors
“Neuroendocrine tumors are rare cancers most often arising in the lungs, pancreas or gastro-intestinal tract. Its behavior can vary greatly …
DR-100 Development of novel diagnostics for personalisation of glioma patient’s therapy based on whole-genome sequencing data and mutational signatures
The main purpose of the research project is to develop new diagnostic biomarkers that will be used for personalised therapy …
DR-097 Molecular mechanisms of interplay between DNA repair pathways in chemotherapy resistance
The main purpose of the research project is to understand the mechanism of interplay between DNA repair pathways associated with …
DR-096 Cisplatin exposure related genomic changes in human germ cell tumors
The nature and impact of genomic changes induced by cisplatin treatment of germ cell tumors is unknown. This is relevant …
Kankers zullen steeds vaker voldoen aan de definitie van ‘zeldzaam’ als het gaat om de moleculaire profielen die elke tumor uniek maakt. Hoe meer onderzoek we hiernaar doen, hoe beter we in de toekomst elke patiënt een op maat gemaakte behandeling kunnen aanbieden. Whole genome sequencing en studies als DRUP leveren hier een belangrijke bijdrage aan.